Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Steering pluripotency and differentiation with N6-methyladenosine RNA modification.

Malla S, Melguizo-Sanchis D, Aguilo F.

Biochim Biophys Acta Gene Regul Mech. 2019 Mar;1862(3):394-402. doi: 10.1016/j.bbagrm.2018.10.013. Epub 2018 Nov 6. Review.

PMID:
30412796
2.

Long non-coding RNA and Polycomb: an intricate partnership in cancer biology.

Achour C, Aguilo F.

Front Biosci (Landmark Ed). 2018 Jun 1;23:2106-2132. Review.

PMID:
29772549
3.

The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer.

Rengasamy M, Zhang F, Vashisht A, Song WM, Aguilo F, Sun Y, Li S, Zhang W, Zhang B, Wohlschlegel JA, Walsh MJ.

Nucleic Acids Res. 2017 Nov 2;45(19):11106-11120. doi: 10.1093/nar/gkx727.

4.

The N6-Methyladenosine RNA modification in pluripotency and reprogramming.

Aguilo F, Walsh MJ.

Curr Opin Genet Dev. 2017 Oct;46:77-82. doi: 10.1016/j.gde.2017.06.006. Epub 2017 Jul 3. Review.

5.

THAP1: Role in Mouse Embryonic Stem Cell Survival and Differentiation.

Aguilo F, Zakirova Z, Nolan K, Wagner R, Sharma R, Hogan M, Wei C, Sun Y, Walsh MJ, Kelley K, Zhang W, Ozelius LJ, Gonzalez-Alegre P, Zwaka TP, Ehrlich ME.

Stem Cell Reports. 2017 Jul 11;9(1):92-107. doi: 10.1016/j.stemcr.2017.04.032. Epub 2017 Jun 1.

6.

RBM5-AS1 Is Critical for Self-Renewal of Colon Cancer Stem-like Cells.

Di Cecilia S, Zhang F, Sancho A, Li S, Aguiló F, Sun Y, Rengasamy M, Zhang W, Del Vecchio L, Salvatore F, Walsh MJ.

Cancer Res. 2016 Oct 1;76(19):5615-5627. Epub 2016 Aug 12.

7.

ZNF217/ZFP217 Meets Chromatin and RNA.

Lee DF, Walsh MJ, Aguiló F.

Trends Biochem Sci. 2016 Dec;41(12):986-988. doi: 10.1016/j.tibs.2016.07.013. Epub 2016 Aug 9.

8.

Structure-Guided Discovery of Selective Antagonists for the Chromodomain of Polycomb Repressive Protein CBX7.

Ren C, Smith SG, Yap K, Li S, Li J, Mezei M, Rodriguez Y, Vincek A, Aguilo F, Walsh MJ, Zhou MM.

ACS Med Chem Lett. 2016 Feb 29;7(6):601-5. doi: 10.1021/acsmedchemlett.6b00042. eCollection 2016 Jun 9.

9.

Deposition of 5-Methylcytosine on Enhancer RNAs Enables the Coactivator Function of PGC-1α.

Aguilo F, Li S, Balasubramaniyan N, Sancho A, Benko S, Zhang F, Vashisht A, Rengasamy M, Andino B, Chen CH, Zhou F, Qian C, Zhou MM, Wohlschlegel JA, Zhang W, Suchy FJ, Walsh MJ.

Cell Rep. 2016 Jan 26;14(3):479-492. doi: 10.1016/j.celrep.2015.12.043. Epub 2016 Jan 7.

10.

Coordination of m(6)A mRNA Methylation and Gene Transcription by ZFP217 Regulates Pluripotency and Reprogramming.

Aguilo F, Zhang F, Sancho A, Fidalgo M, Di Cecilia S, Vashisht A, Lee DF, Chen CH, Rengasamy M, Andino B, Jahouh F, Roman A, Krig SR, Wang R, Zhang W, Wohlschlegel JA, Wang J, Walsh MJ.

Cell Stem Cell. 2015 Dec 3;17(6):689-704. doi: 10.1016/j.stem.2015.09.005. Epub 2015 Oct 29.

11.

Long Non-coding RNA ANRIL and Polycomb in Human Cancers and Cardiovascular Disease.

Aguilo F, Di Cecilia S, Walsh MJ.

Curr Top Microbiol Immunol. 2016;394:29-39. doi: 10.1007/82_2015_455. Review.

12.

CHD6 regulates the topological arrangement of the CFTR locus.

Sancho A, Li S, Paul T, Zhang F, Aguilo F, Vashisht A, Balasubramaniyan N, Leleiko NS, Suchy FJ, Wohlschlegel JA, Zhang W, Walsh MJ.

Hum Mol Genet. 2015 May 15;24(10):2724-32. doi: 10.1093/hmg/ddv032. Epub 2015 Jan 28.

13.

Burkitt's lymphoma treatment in a rural hospital in Sierra Leone.

San Roman M, Aguilo F, Clapes M, Sheku M, Dawoh P, Mora J, Cruz O.

Trans R Soc Trop Med Hyg. 2013 Oct;107(10):653-9. doi: 10.1093/trstmh/trt069. Epub 2013 Sep 10.

PMID:
24021903
14.

Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.

Ferrer M, Guedea F, Suárez JF, de Paula B, Macías V, Mariño A, Hervás A, Herruzo I, Ortiz MJ, Ponce de León J, Sancho G, Boladeras A, Ayala A, Craven-Bratle J, Ávila M, Cunillera O, Pardo Y, Alonso J, Aguiló F; Clinically Localized Prostate Cancer.

Radiother Oncol. 2013 Aug;108(2):306-13. doi: 10.1016/j.radonc.2013.05.038. Epub 2013 Jul 9.

PMID:
23849168
15.

Interplay between Homeobox proteins and Polycomb repressive complexes in p16INK⁴a regulation.

Martin N, Popov N, Aguilo F, O'Loghlen A, Raguz S, Snijders AP, Dharmalingam G, Li S, Thymiakou E, Carroll T, Zeisig BB, So CW, Peters G, Episkopou V, Walsh MJ, Gil J.

EMBO J. 2013 Apr 3;32(7):982-95. doi: 10.1038/emboj.2013.37. Epub 2013 Mar 1.

16.

Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling.

Lee DF, Su J, Ang YS, Carvajal-Vergara X, Mulero-Navarro S, Pereira CF, Gingold J, Wang HL, Zhao R, Sevilla A, Darr H, Williamson AJ, Chang B, Niu X, Aguilo F, Flores ER, Sher YP, Hung MC, Whetton AD, Gelb BD, Moore KA, Snoeck HW, Ma'ayan A, Schaniel C, Lemischka IR.

Cell Stem Cell. 2012 Aug 3;11(2):179-94. doi: 10.1016/j.stem.2012.05.020.

17.

Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-β2 and FLT3 in hematopoiesis.

Avagyan S, Aguilo F, Kamezaki K, Snoeck HW.

Blood. 2011 Dec 1;118(23):6078-86. doi: 10.1182/blood-2011-07-365080. Epub 2011 Oct 3.

18.

Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression.

Aguilo F, Zhou MM, Walsh MJ.

Cancer Res. 2011 Aug 15;71(16):5365-9. doi: 10.1158/0008-5472.CAN-10-4379. Epub 2011 Aug 9. Review.

19.

Prdm16 is a physiologic regulator of hematopoietic stem cells.

Aguilo F, Avagyan S, Labar A, Sevilla A, Lee DF, Kumar P, Lemischka IR, Zhou BY, Snoeck HW.

Blood. 2011 May 12;117(19):5057-66. doi: 10.1182/blood-2010-08-300145. Epub 2011 Feb 22.

20.

[Cost comparison of three treatments for localized prostate cancer in Spain: radical prostatectomy, prostate brachytherapy and external 3D conformal radiotherapy].

Becerra Bachino V, Cots F, Guedea F, Pera J, Boladeras A, Aguiló F, Suárez JF, Gallo P, Murgui L, Pont A, Cunillera O, Pardo Y, Ferrer M; Grupo Multicéntrico Español de Cáncer de Próstata Organoconfinado.

Gac Sanit. 2011 Jan-Feb;25(1):35-43. doi: 10.1016/j.gaceta.2010.10.008. Spanish.

21.

Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment.

Pardo Y, Guedea F, Aguiló F, Fernández P, Macías V, Mariño A, Hervás A, Herruzo I, Ortiz MJ, Ponce de León J, Craven-Bratle J, Suárez JF, Boladeras A, Pont À, Ayala A, Sancho G, Martínez E, Alonso J, Ferrer M.

J Clin Oncol. 2010 Nov 1;28(31):4687-96. doi: 10.1200/JCO.2009.25.3245. Epub 2010 Oct 4. Erratum in: J Clin Oncol. 2011 Feb 20;29(6):779.

PMID:
20921463
22.

Transcriptional regulation of the human acetoacetyl-CoA synthetase gene by PPARgamma.

Aguiló F, Camarero N, Relat J, Marrero PF, Haro D.

Biochem J. 2010 Mar 29;427(2):255-64. doi: 10.1042/BJ20090851.

PMID:
20102333
23.

Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience.

Guedea F, Ferrer M, Pera J, Aguiló F, Boladeras A, Suárez JF, Cunillera O, Ferrer F, Pardo Y, Martínez E, Ventura M.

Clin Transl Oncol. 2009 Jul;11(7):470-8.

PMID:
19574206
24.

Altered expression of 12S/MT-RNR1, MT-CO2/COX2, and MT-ATP6 mitochondrial genes in prostate cancer.

Abril J, de Heredia ML, González L, Clèries R, Nadal M, Condom E, Aguiló F, Gómez-Zaera M, Nunes V.

Prostate. 2008 Jul 1;68(10):1086-96. doi: 10.1002/pros.20771.

PMID:
18409190
25.

Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.

Ferrer M, Suárez JF, Guedea F, Fernández P, Macías V, Mariño A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, Craven-Bratle J, Garin O, Aguiló F; Multicentric Spanish Group of Clinically Localized Prostate Cancer.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):421-32. doi: 10.1016/j.ijrobp.2007.12.024. Epub 2008 Mar 5.

PMID:
18325680
26.

Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility.

Solé X, Hernández P, de Heredia ML, Armengol L, Rodríguez-Santiago B, Gómez L, Maxwell CA, Aguiló F, Condom E, Abril J, Pérez-Jurado L, Estivill X, Nunes V, Capellá G, Gruber SB, Moreno V, Pujana MA.

BMC Genomics. 2008 Jan 11;9:12. doi: 10.1186/1471-2164-9-12.

27.

Aneuploidy of chromosome Y in prostate tumors and seminal vesicles: a possible sign of aging rather than an indicator of carcinogenesis?

Nadal M, Pera G, Pujadas J, Abril J, González L, Aguiló F, Condom E, Gómez-Zaera M, Nunes V.

Mol Carcinog. 2007 Jul;46(7):543-52.

PMID:
17295237
28.

[Diagnostic methodology for the biochemical recurrence of prostate cancer after brachytherapy].

Novo JF, López SP, Aguiló FL, Miranda EF.

Arch Esp Urol. 2006 Dec;59(10):1063-7. Review. Spanish.

PMID:
17283719
29.

Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer.

Guedea F, Aguilo F, Polo A, Langley S, Laing R, Henderson A, Aaltomaa S, Kataja V, Palmgren J, Bladou F, Salem N, Gravis G, Losa A, Guazzoni G, Nava L.

Radiother Oncol. 2006 Jul;80(1):57-61. Epub 2006 Jul 10.

PMID:
16831480
30.

Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients.

Gómez-Zaera M, Abril J, González L, Aguiló F, Condom E, Nadal M, Nunes V.

Mutat Res. 2006 Mar 20;595(1-2):42-51.

PMID:
16472830
31.

Tissue imprints or primary cultures: which strategy to use to study cytogenetic clonality?

Nadal M, Pera G, Gómez-Zaera M, Abril J, Suárez JF, Aguiló F, Condom E, Nunes V.

Diagn Mol Pathol. 2005 Dec;14(4):243-6.

PMID:
16319695
32.

European collaborative group on prostate brachytherapy: preliminary report in 1175 patients.

Langley S, Laing R, Henderson A, Aaltomaa S, Kataja V, Palmgren JE, Bladou F, Salem N, Serment G, Nava L, Losa A, Guazzoni G, Guedea F, Aguilo F, Suarez JF.

Eur Urol. 2004 Nov;46(5):565-70; discussion 570.

PMID:
15474264
33.

Clinical profile of 128 subjects operated for primary hyperparathyroidism.

Haddock L, Aguiló F Jr, Vázquez Quintana E, Vázquez MC, Rabell V, Allende M.

P R Health Sci J. 1998 Dec;17(4):309-16.

PMID:
10028537
34.

Recurrent ectopic adrenocorticotropic hormone producing thymic carcinoid detected with octreotide imaging.

Silva F, Vázquez-Sellés J, Aguilö F, Vázquez G, Flores C.

Clin Nucl Med. 1999 Feb;24(2):109-10.

PMID:
9988068
35.

An update on the discovery, pathophysiological actions, clinical manifestations and possible physiology of parathyroid related peptide.

Alcantara A, Montalvo-Figueroa JA, Toro S, Aguilo F.

P R Health Sci J. 1997 Mar;16(1):15-22. Review.

PMID:
9160398
36.

Pericardial effusion. Unusual complication in thyroid cancer.

Silva F, Garcia L, Flores C, Storer D, Aguiló F.

Clin Nucl Med. 1996 Mar;21(3):218-20.

PMID:
8846567
37.

The lumbar and femoral bone mineral densities in a normal female Puerto Rican population.

Haddock L, Ortiz V, Vázquez MD, Aguiló F, Bernard E, Ayala A, Mejías N.

P R Health Sci J. 1996 Mar;15(1):5-11.

PMID:
8744861
38.

Unusual cases of hyperparathyroidism.

Vázquez-Quintana E, Haddock L, Aguiló F, Sotomayor R, Ramírez M, Vázquez-Plard J, Rabell V, Pagán Sáez H.

P R Health Sci J. 1995 Sep;14(3):227-32. Review.

PMID:
8588025
39.

Current status of primary hyperparathyroidism.

Aguiló F Jr.

P R Health Sci J. 1995 Sep;14(3):191-3. No abstract available.

PMID:
8588019
40.

Bone densitometric profile among young adults in Puerto Rico: morphometric and SPA results.

Hernández DI, Aguiló F Jr.

P R Health Sci J. 1994 Dec;13(4):241-6.

PMID:
7899541
41.

[Malignant neoplasms and kidney transplantation].

Serrallach N, Riera LL, Franco E, Aguiló F, Muñoz J, López-Costea MA, Camps N, Serra J, González C, Castelao AM.

Actas Urol Esp. 1994 Sep;18(8):801-7. Spanish.

PMID:
7998508
42.

[BCG in superficial carcinoma of the bladder. Authors' experience].

Bordalba Gómez JR, Muñoz Segui J, Aguilo F, Gil Vernet A, Vigues F, Lopez Costea MA, Serrallach N.

Actas Urol Esp. 1992 Jun;16(6):443-5. Spanish.

PMID:
1509911
43.

[Therapeutic embolization of a renal angiomyolipoma associated with tuberous sclerosis].

Perez Cespedes M, Tesedo X, Aguilo F, Torrecilia C, Munoz J, Serrallach N.

J Urol (Paris). 1992;98(2):112-5. French.

PMID:
1431185
44.

Pheochromocytoma: a twenty year experience at the University Hospital.

Aguiló F, Tamayo N, Vázquez-Quintana E, Rabell V, Haddock L, Allende M, Pagán H, González A.

P R Health Sci J. 1991 Dec;10(3):135-42. Review. Erratum in: P R Health Sci J 1992 Apr;11(1):6.

PMID:
1775616
45.

[Renal mass as the initial manifestation of a metastasized oat-cell].

Pérez Céspedes M, Armora J, Aguiló F, Muñoz J, Orejas V, Torrecilla C, Serrallach N.

Actas Urol Esp. 1991 Mar-Apr;15(2):202-4. Spanish.

PMID:
1666939
46.

Localization of parathyroid lesions: blind study for surgeons.

Vázquez Quintana E, Quintana CS, Aguiló F Jr, Pagán-Sáez H, Silva F.

Bol Asoc Med P R. 1989 Sep;81(9):342-4.

PMID:
2684194
47.

[Hormonal treatment of cancer of the prostate].

Aguiló F, Torrecilla C, Muñoz J, Tesedo X, Vigués F, Serrallach N.

Actas Urol Esp. 1989 Jul-Aug;13(4):256-63. Review. Spanish.

PMID:
2678937
48.

Hyperprolactinemia and its management.

Otero JR, Baco F, Aguiló F.

Bol Asoc Med P R. 1989 Jun;81(6):209-13. No abstract available.

PMID:
2765039
49.
50.

Salivary testosterone in prostatic carcinoma.

Navarro MA, Aguiló F, Villabona CM, Torrecilla C, Bonnin R.

Br J Urol. 1989 Mar;63(3):306-8.

PMID:
2702429

Supplemental Content

Loading ...
Support Center